What changedRaised $2.1B in Series B funding, led by Thrive Capital.
The company said the funding supports accelerate the development and deployment of its AI drug design engine (IsoDDE), expand its pipeline of therapeutic programs toward clinical trials, and scale its global workforce across AI, engineering, and clinical disciplines.
Likely next AfterRaise intelligenceNew market entryFirst local hires in the new marketLocal entity and legal setup
Where help may be relevant AfterRaise intelligenceClinical operationsScientific hiringLicensing and BD partnershipsMarket-entry advisersLocal employment infrastructure
Approach preferences not yet specified